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Abstract: Zika virus (ZIKV) causes no-to-mild symptoms or severe neurological disorders.
To investigate the importance of viral and host genetic variations in determining ZIKV infection
outcomes, we created three full-length infectious cDNA clones as bacterial artificial chromosomes
for each of three spatiotemporally distinct and genetically divergent ZIKVs: MR-766 (Uganda,
1947), P6-740 (Malaysia, 1966), and PRVABC-59 (Puerto Rico, 2015). Using the three molecularly
cloned ZIKVs, together with 13 ZIKV region-specific polyclonal antibodies covering nearly the entire
viral protein-coding region, we made three conceptual advances: (i) We created a comprehensive
genome-wide portrait of ZIKV gene products and their related species, with several previously
undescribed gene products identified in the case of all three molecularly cloned ZIKVs. (ii) We found
that ZIKV has a broad cell tropism in vitro, being capable of establishing productive infection in 16 of
17 animal cell lines from 12 different species, although its growth kinetics varied depending on both
the specific virus strain and host cell line. More importantly, we identified one ZIKV-non-susceptible
bovine cell line that has a block in viral entry but fully supports the subsequent post-entry steps.
(iii) We showed that in mice, the three molecularly cloned ZIKVs differ in their neuropathogenicity,
depending on the particular combination of viral and host genetic backgrounds, as well as in the
presence or absence of type I/II interferon signaling. Overall, our findings demonstrate the impact
of viral and host genetic variations on the replication kinetics and neuropathogenicity of ZIKV and
provide multiple avenues for developing and testing medical countermeasures against ZIKV.
Keywords: Zika virus; flavivirus; infectious cDNA; replication; gene expression; neuropathogenesis;
viral genetic variation; host genetic variation

1. Introduction
Discovered in Uganda in 1947 in a febrile rhesus macaque [1], Zika virus (ZIKV) is a medically
important flavivirus [2] related to Japanese encephalitis (JEV), West Nile (WNV), dengue, and yellow
fever viruses [3]. Originally, it was confined within an equatorial belt running from Africa to Asia,
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with only about a dozen cases of human illness reported [4]. In 2007, however, it caused a major
outbreak of mild illness characterized by fever, rash, arthralgia, and conjunctivitis on the western
Pacific Island of Yap [5,6]. Since then, it has spread eastward across the Pacific Ocean, invading
French Polynesia and other Pacific Islands in 2013–2014 [7], reaching the Americas and Caribbean in
2015–2016 [8,9], and now threatening much of the world [10,11]. ZIKV is spread to humans mainly
through the bite of an infected Aedes species mosquito, e.g., Aedes aegypti or Aedes albopictus [12],
but it can also be transmitted from a mother to her child during pregnancy [13,14] or through sexual
contact [15,16]. Serious concerns have been raised over links to congenital neurological malformations
(e.g., microcephaly) and severe neurological complications (e.g., Guillain–Barré syndrome) [17,18].
Despite its continuous rapid spread and high pandemic potential, no vaccine or drug is available to
prevent or treat ZIKV infection.
ZIKV is an enveloped RNA virus with a nucleocapsid core comprising an ~11 kb plus-strand
RNA genome and multiple copies of the C protein; this core is surrounded by a lipid bilayer bearing
the anchored M and E proteins [19,20]. With regard to the molecular events that occur during ZIKV
infection, our current understanding of the molecular biology of closely related flaviviruses offers a
promising starting point for ZIKV research [21]. As the first step in flavivirus replication, the virion
binds to one or more cellular proteins on the surface of a host cell, and is then internalized via
clathrin-mediated endocytosis in a viral glycoprotein E-dependent manner [22–24]. Within endosomes,
the E glycoprotein undergoes low pH-induced conformational changes, followed by fusion of the viral
and host cell membranes [25–27]. In the cytoplasm, the viral genomic RNA functions initially as an
mRNA for the translation of a single long open reading frame (ORF) flanked by 50 and 30 non-coding
regions (NCRs) [28,29]; the resulting polyprotein is cleaved by viral and cellular proteases to generate
at least 10 mature proteins [30,31]: three structural (C, prM, and E) and seven nonstructural (NS1, 2A,
2B, 3, 4A, 4B, and 5). In JEV and WNV, ribosomal frameshifting is also used for the expression of
NS1’, a C-terminally extended form of NS1 [32–34]. A complex of the seven nonstructural proteins
directs viral RNA replication on the distinct virus-induced membranous compartments derived from
endoplasmic reticulum (ER) [35,36]. This replication process is catalyzed by two main viral components:
(i) NS3, with serine protease (and its cofactor, NS2B) and RNA helicase/NTPase/RTPase activity,
and (ii) NS5, with methyltransferase/guanylyltransferase and RNA-dependent RNA polymerase
activity [37]. Virus assembly begins with budding of the C proteins, complexed with a newly made viral
genomic RNA, into the ER lumen, and acquisition of the viral prM and E proteins. The prM-containing
immature virions travel through the secretory pathway; in the trans-Golgi network, a cellular furin-like
protease cleaves prM to yield the mature M protein, converting the immature particle to a mature
virion [38].
The clinical presentation of ZIKV infection is highly variable, ranging from no apparent symptoms
or mild self-limiting illness, to severe neurological disorders, such as microcephaly and Guillain–Barré
syndrome [10,17]. Fundamentally, the varied outcomes after infection with a pathogen depend on the
specific combination of pathogen and host genotypes [39]. On the virus side, a limited but significant
number of ZIKVs have been isolated from Africa, Asia, and the Americas during the past 70 years.
Recent phylogenetic analyses based on complete or near-complete viral genome sequences have
revealed that the spatiotemporally distinct ZIKV strains are grouped into two major genetic lineages,
African and Asian, with the 2015–2016 American epidemic strains originating from a common ancestor
of the Asian lineage [40–42]. Despite the continuous expansion of its genetic diversity, little is known
about the effect of viral genetic variation on the pathogenicity of ZIKV between the two lineages or
between different strains within a particular lineage. On the host side, much progress has recently been
made in developing murine models for ZIKV infection [43], including mice genetically engineered to
lack one or more components of the innate and adaptive immune systems that affect the development,
severity, and progression of ZIKV-induced disease [44–49]. However, the influence of host genetic
variation on susceptibility to ZIKV infection is largely unknown.
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To assess, experimentally, the impact of viral and host genetic variations on the outcome of ZIKV
infection, we have now generated (i) a unique panel of three functional bacterial artificial chromosomes
(BACs), each containing a full-length infectious cDNA for one of three genetically divergent ZIKV
strains, and (ii) an exclusive collection of 13 rabbit antisera capable of detecting almost all of the
ZIKV gene products and their related species. Using these functional genomics and immunologic
tools, together with various cell culture and mouse infection model systems, we show that the three
molecularly defined cDNA-derived ZIKVs have a similar viral protein expression profile, but display
biologically significant differences in in vitro growth properties and in vivo neuropathogenic potential
that depend on both viral and host genetic traits. Our study not only provides a powerful system for
the functional study of viral and host genetics in ZIKV replication and pathogenesis, but also offers a
valuable platform for the rational design of vaccines and therapeutics against ZIKV.
2. Materials and Methods
2.1. Cells and Viruses
Details of the 17 cell lines used in this study, including their growth medium and culture
conditions, are presented in Table 1. ZIKV MR-766 and P6-740 were obtained from the World Reference
Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch (Galveston, TX,
USA), and ZIKV PRVABC-59 was provided by the Centers for Disease Control and Prevention (Fort
Collins, CO, USA). In the case of all three ZIKVs, viral stocks were amplified once in Vero cells at a
multiplicity of infection (MOI) of 1.
Table 1. Cells used in this study.
Organism

Cell

Tissue

Growth Medium a

Culture
Condition

Source (Catalog
Number) b

Human

HEK

Embryo, kidney

37o C, 5% CO2

Human

Huh-7

Liver

Human

SH-SY5Y

Bone marrow

Mouse

MEF

Mouse

NIH/3T3

DMEM supplemented with 10% FBS and PS

37o C, 5% CO2

Mouse

NSC-34

DMEM (without SP) supplemented with 10% FBS and PS

37o C, 5% CO2

Monkey

Vero

Embryo (C57BL/6),
fibroblast
Embryo (NIH/Swiss),
fibroblast
Motor neuron-like
hybrid
Kidney

MEM supplemented with 10% FBS, 2 mM L-glutamine, 0.1
mM NEAA, 1.0 mM SP, and PS
DMEM supplemented with 10% FBS, 0.1 mM NEAA, and
PS
A 1:1 mixture of MEM and Ham's F-12 nutrient medium
supplemented with 10% FBS, 0.1 mM NEAA, and PS
DMEM supplemented with 10% FBS and PS

α-MEM supplemented with 10% FBS and PS

37o C, 5% CO2

Cow

BT

Turbinate

DMEM (without SP) supplemented with 10% HS and PS

37o C, 5% CO2

Cow

MDBK

Kidney

DMEM (without SP) supplemented with 10% HS and PS

37o C, 5% CO2

Pig

ST

Testis

α-MEM supplemented with 10% FBS and PS

37o C, 5% CO2

Sheep

SFF-6

Fetus, fibroblast

DMEM supplemented with 15% FBS and PS

37o C, 5% CO2

Goat

GFF-4

Fetus, fibroblast

DMEM supplemented with 15% FBS and PS

37o C, 5% CO2

Horse

NBL-6

Skin, dermis

EMEM supplemented with 10% FBS and PS

37o C, 5% CO2

Dog

MDCK

Kidney

37o C, 5% CO2

Cat

CRFK

Kidney, cortex

Chicken

CEF

Embryo, fibroblast

MEM supplemented with EBSS, 10% FBS, 0.1 mM NEAA,
1.0 mM SP, and PS
MEM supplemented with EBSS, 10% HS, 0.1 mM NEAA,
1.0 mM SP, and PS
DMEM supplemented with 10% FBS and PS

Mosquito

C6/36

Larva (Aedes albopictus)

MEM supplemented with EBSS, 10% FBS, 2 mM
L-glutamine, 0.1 mM NEAA, 1.0 mM SP, and PS

28o C, 5% CO2

ATCC
(CRL-1573)
Charles M. Rice,
RU
ATCC
(CRL-2266)
ATCC
(SCRC-1008)
ATCC
(CRL-1658)
Cedarlane
(CLU140)
ATCC
(WHO-Vero)
ATCC
(CRL-1390)
ATCC
(CCL-22)
ATCC
(CRL-1746)
Irina A.
Polejaeva,
USU
Irina A.
Polejaeva,
USU
ATCC
(CCL-57)
ATCC
(CCL-34)
ATCC
(CCL-94)
Sung-June Byun,
KNIAS
ATCC
(CRL-1660)

a

37o C, 5% CO2
37o C, 5% CO2
37o C, 5% CO2

37o C, 5% CO2
37o C, 5% CO2

MEM, minimum essential medium; α-MEM, alpha minimum essential medium; DMEM, Dulbecco’s modified
eagle medium; EMEM, Eagle’s minimum essential medium; EBSS, Earle’s balanced salt solution; FBS, fetal bovine
serum; HS, horse serum; NEAA, nonessential amino acids; SP, sodium pyruvate; PS, penicillin-streptomycin.
b ATCC, American Type Culture Collection; RU, Rockefeller University; USU, Utah State University; KNIAS, Korea
National Institute of Animal Science.
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2.2. Sequence Alignment and Phylogenetic Analysis
Multiple sequence alignments were performed via ClustalX, and the phylogenetic tree was
constructed using MEGA and visualized via TreeView, as described [50]. Sequence identities between
aligned nucleotide and amino acid sequences were calculated using ClustalX.
2.3. Cloning
Standard molecular cloning techniques were used to create three full-length ZIKV cDNAs [51],
one each for MR-766, P6-740, and PRVABC-59 in the BAC plasmid pBeloBAC11 [52], designated
pBac/MR-766, pBac/P6-740, and pBac/PRVABC-59. The same cloning strategy was used to construct
all three full-length ZIKV cDNAs with the appropriate primer sets listed in Table 2. Essentially,
each full-length ZIKV cDNA flanked by the 50 SP6 promoter and the 30 PsrI/BarI restriction enzyme
site was created by joining five overlapping RT-PCR-generated cDNA fragments at four natural
restriction enzyme sites found in the viral genome (see below for detailed description of cloning
strategy). The cloned cDNAs were checked by restriction enzyme mapping and sequencing.
Table 2. Oligonucleotides used in this study.
Oligonucleotide

Sequence a (5’ to 3’)

Position b

Direction

Z1RT
Z1F
Z1R
Z2RT
Z2F
Z2R
Z3RT
Z3F
Z3R
S123-5sp1F
S123-5sp1R
S1-5sp2F
S1-5sp2R
S1-3roF
S1-3roR
S23-5sp2F
S23-5sp2R
S23-3roF
S23-3roR
ZikaC-F
ZikaC-R
ZikaM-F
ZikaM-R
ZikaE-F
ZikaE-R
ZikaNS4A-F
ZikaNS4A-R
ZikaNS4B-F
ZikaNS4B-R
ZikaF
ZikaR
ZikaProbe
VeroF
VeroR
VeroProbe

GCTATTGGGTTCATGCCACAGATGGTCATCA
tatgtttaaacAGTTGTTGATCTGTGTGAATCAGACTGCGA
tatggcgcgccAGGACCACCTTGAGTATGATCTCTCTCATG
ATTGTCATTGTGTCAATGTCAGTCACCACTA
tatgtttaaacTCATTGTTTGGAGGAATGTCCTGGTTCTCA
tatggcgcgccTCAATGTCAGTCACCACTATTCCATCCACA
CTCCAGTTCAGGCCCCAGATTGAAGGGTGGGG
tatgtttaaacGGAAGTCCCAGAGAGAGCCTGGAGCTCAGG
tatggcgcgccAAGGGTGGGGAAGGTCGCCACCTTCTTTTC
ctaggatccttaattaacctgcagggggctgtta
GATCAACAACTctatagtgtcccctaaatc
ggacactatagAGTTGTTGATCTGTGTGAGTC
tatccgcggTAGCGCAAACCCGGGGTTCCTGAAT
tatccgcggGGAAAAAGGGAGGACTTATGGTGTG
agggcggccgcgtatgtcgcgttccgtacgttctagAGAAACCATGGATTTCCCCACACC
ggacactatagAGTTGTTGATCTGTGTGAATC
tatccgcggAACGCAAAGCCAGGGTTCCTGAATA
tatccgcggGGGAAAAAGGGAAGACTTATGGTGT
agggcggccgcgtatgtcgccttccgtacgttctagAGACCCATGGATTTCCCCACACCG
tttgaattcGGTCTCATCAATAGATGGGGT
tttctcgagctattaTCGTCTCTTCTTCTCCTTCCT
tttgaattcGCTGTGACGCTCCCCTCCCAT
tttctcgagctattaGACTCTAATCAAGTGCTTTGT
tttgaattcCAGCACAGTGGGATGATCGTT
tttctcgagctattaTCCTAGGCTTCCAAAACCCCC
tttgaattcGGAGCGGCTTTTGGAGTGATG
tttctcgagctattaGGTCTCCGGCAATTGGGCCGC
tttgaattcGTGACTGACATTGACACAATG
tttctcgagctattaGGAAGTTGCGGCTGTGATCAG
GAAGTGGAAGTCCCAGAGAG
TGCTGAGCTGTATGACCCG
FAM-TGGAGCTCAGGCTTTGATTGGGTGAC-BHQ1
AGCGGGAAATCGTGCGTGAC
CAATGGTGATGACCTGGCCA
HEX-CACGGCGGCTTCTAGCTCCTCCC-BHQ2

4531–4561
1–30
4502–4531
7369–7399
2340–2369
7358–7387
10603–10634
5627–5656
10583–10612

Reverse
Forward
Reverse
Reverse
Forward
Reverse
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Forward
Reverse
Forward

1–11
1–21
860–884
10191–10215
10785–10807
1–21
859–883
10190–10214
10784–10807
297–317
399–419
753–773
828–848
1416–1436
1518–1538
6465–6485
6597–6617
7374–7394
7506–7526
5622–5641
5757–5775
5646–5671
624–643
742–761
694–716

a

ZIKV-specific sequences are indicated in uppercase normal letters, and Vero β-actin-specific sequences are shown
in uppercase italic letters. Other nonviral sequences are indicated in lowercase letters. Restriction enzyme sites
used for cDNA cloning are underlined. FAM, 6-Carboxyfluorescein; HEX, Hexachlorofluorescein; BHQ, Black hole
quencher. b Nucleotide position refers to the complete genome sequence of ZIKV PRVABC-59 (GenBank accession
number KX377337) or to the mRNA sequence of Vero β-actin (GenBank accession number AB004047).

(1) pBac/MR-766: The genomic RNA of ZIKV MR-766 (GenBank accession no. KX377335)
was used as a template for the synthesis of three overlapping cDNA fragments by RT-PCR with
the following primer sets: Frag-AMR-766 (4552 bp), Z1RT, and Z1F + Z1R; Frag-BMR-766 (5070 bp),
Z2RT, and Z2F + Z2R; and Frag-CMR-766 (5008 bp), Z3RT, and Z3F + Z3R. Each of the three cDNA
amplicons was subcloned into pBACSP6 /JVFLx/XbaI [53], a derivative of the pBeloBAC11 plasmid,
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by ligating the 8381 bp PmeI-MluI fragment of pBACSP6 /JVFLx/XbaI with the 4538, 5056, and 4994
bp PmeI-AscI fragments of the Frag-AMR-766 , Frag-BMR-766 , and Frag-CMR-766 amplicons, respectively.
This generated pBac/Frag-AMR-766 to -CMR-766 . To introduce an SP6 promoter immediately upstream
of the first adenine residue of the viral genome, two cDNA fragments were first amplified individually
by (i) PCR of pBACSP6 /JVFLx/XbaI with a pair of primers, S123-5sp1F + S123-5sp1R (S123-5sp1R
contains the antisense sequence of the SP6 promoter) and (ii) PCR of pRs/50 NCRMR-766 [54] with
another pair of primers, S1-5sp2F + S1-5sp2R. Subsequently, these two fragments were fused by a
second round of PCR with the outer forward and reverse primers S123-5sp1F + S1-5sp2R. The 1025
bp BamHI-SacII fragment of the fused PCR amplicons was ligated with the 2718 bp BamHI-SacII
fragment of pRs2, creating pRs/50 SPMR-766 . To engineer a unique PsrI run-off site just downstream
of the last thymine residue of the viral genome, one cDNA fragment was amplified by PCR of
pRs/30 NCRMR-766 [54] with primers S1-3roF + S1-3roR (S1-3roR contains the antisense sequence of the
PsrI and NotI recognition sites in a row). The 649 bp SacII-NotI fragment of the resulting amplicons was
ligated with the 2667 bp SacII-NotI fragment of pRs2, creating pRs/30 ROMR-766 . The full-length MR-766
cDNA clone pBac/MR-766 was then assembled by sequentially joining the 7456 bp PacI-NotI fragment
of pBACSP6 /JVFLx/XbaI with the following five DNA fragments: (i) the 1004 bp PacI-XmaI fragment of
pRs/5’SPMR-766 , (ii) the 3160 bp XmaI-XhoI fragment of pBac/Frag-AMR-766 , (iii) the 3144 bp XhoI-NsiI
fragment of pBac/Frag-BMR-766 , (iv) the 3041 bp NsiI-BamHI fragment of pBac/Frag-CMR-766 , and (v)
the 619 bp BamHI-NotI fragment of pRs/30 ROMR-766 .
(2) pBac/P6-740: The genomic RNA of ZIKV P6-740 (GenBank accession no. KX377336) was used
as a template for the synthesis of three overlapping cDNA fragments by RT-PCR with the following
primer sets: Frag-AP6-740 (4553 bp), Z1RT, and Z1F + Z1R; Frag-BP6-740 (5070 bp), Z2RT, and Z2F + Z2R;
and Frag-CP6-740 (5008 bp), Z3RT, and Z3F + Z3R. Each of the three cDNA amplicons was subcloned
into pBACSP6 /JVFLx/XbaI, by ligating the 8381 bp PmeI-MluI fragment of pBACSP6 /JVFLx/XbaI with
the 4539, 5056, and 4994 bp PmeI-AscI fragments of the Frag-AP6-740 , Frag-BP6-740 , and Frag-CP6-740
amplicons, respectively. This generated pBac/Frag-AP6-740 to -CP6-740 . To introduce an SP6 promoter
immediately upstream of the first adenine residue of the viral genome, two cDNA fragments were
first amplified individually by (i) PCR of pBACSP6 /JVFLx/XbaI with a pair of primers, S123-5sp1F
+ S123-5sp1R (S123-5sp1R contains the antisense sequence of the SP6 promoter) and (ii) PCR of
pRs/50 NCRP6-740 [54] with another pair of primers, S23-5sp2F + S23-5sp2R. Subsequently, these two
fragments were fused by a second round of PCR with the outer forward and reverse primers S123-5sp1F
+ S23-5sp2R. The 1025 bp BamHI-SacII fragment of the fused PCR amplicons was ligated with the
2718 bp BamHI-SacII fragment of pRs2, creating pRs/50 SPP6-740 . To engineer a unique BarI run-off site
just downstream of the last thymine residue of the viral genome, one cDNA fragment was amplified
by PCR of pRs/30 NCRP6-740 [54] with primers S23-3roF + S23-3roR (S23-3roR contains the antisense
sequence of the BarI and NotI recognition sites in a row). The 649 bp SacII-NotI fragment of the resulting
amplicons was ligated with the 2667 bp SacII-NotI fragment of pRs2, creating pRs/30 ROP6-740 . The
full-length P6-740 cDNA clone pBac/P6-740 was then assembled by sequentially joining the 7456
bp PacI-NotI fragment of pBACSP6 /JVFLx/XbaI with the following five DNA fragments: (i) the 187
bp PacI-NheI fragment of pRs/50 SPP6-740 , (ii) the 2930 bp NheI-SpeI fragment of pBac/Frag-AP6-740 ,
(iii) the 3359 bp SpeI-NgoMIV fragment of pBac/Frag-BP6-740 , (iv) the 4059 bp NgoMIV-StuI fragment
of pBac/Frag-CP6-740 , and (v) the 433 bp StuI-NotI fragment of pRs/30 ROP6-740 .
(3) pBac/PRVABC-59: The genomic RNA of ZIKV PRVABC-59 (GenBank accession no. KX377337)
was used as a template for the synthesis of three overlapping cDNA fragments by RT-PCR with
the following primer sets: Frag-APRVABC-59 (4553 bp), Z1RT, and Z1F + Z1R; Frag-BPRVABC-59
(5070 bp), Z2RT, and Z2F + Z2R; and Frag-CPRVABC-59 (5008 bp), Z3RT, and Z3F + Z3R. Each of
the three cDNA amplicons was subcloned into pBACSP6 /JVFLx/XbaI, by ligating the 8381 bp
PmeI-MluI fragment of pBACSP6 /JVFLx/XbaI with the 4539, 5056, and 4994 bp PmeI-AscI fragments
of the Frag-APRVABC-59 , Frag-BPRVABC-59 , and Frag-CPRVABC-59 amplicons, respectively. This generated
pBac/Frag-APRVABC-59 to -CPRVABC-59 . To introduce an SP6 promoter immediately upstream of the first
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adenine residue of the viral genome, two cDNA fragments were first amplified individually by (i) PCR
of pBACSP6 /JVFLx/XbaI with a pair of primers, S123-5sp1F + S123-5sp1R (S123-5sp1R contains the
antisense sequence of the SP6 promoter) and (ii) PCR of pRs/50 NCRPRVABC-59 [54] with another pair of
primers, S23-5sp2F + S23-5sp2R. Subsequently, these two fragments were fused by a second round of
PCR with the outer forward and reverse primers S123-5sp1F + S23-5sp2R. The 1025 bp BamHI-SacII
fragment of the fused PCR amplicons was ligated with the 2718 bp BamHI-SacII fragment of pRs2,
creating pRs/50 SPPRVABC-59 . To engineer a unique BarI run-off site just downstream of the last thymine
residue of the viral genome, one cDNA fragment was amplified by PCR of pRs/30 NCRPRVABC-59 [54]
with primers S23-3roF + S23-3roR (S23-3roR contains the antisense sequence of the BarI and NotI
recognition sites in a row). The 649 bp SacII-NotI fragment of the resulting amplicons was ligated with
the 2667 bp SacII-NotI fragment of pRs2, creating pRs/30 ROPRVABC-59 . The full-length PRVABC-59
cDNA clone pBac/PRVABC-59 was then assembled by sequentially joining the 7456 bp PacI-NotI
fragment of pBACSP6 /JVFLx/XbaI with the following five DNA fragments: (i) the 187 bp PacI-NheI
fragment of pRs/50 SPPRVABC-59 , (ii) the 4426 bp NheI-EcoNI fragment of pBac/Frag-APRVABC-59 , (iii) the
2114 bp EcoNI-SacII fragment of pBac/Frag-BPRVABC-59 , (iv) the 3808 bp SacII-StuI fragment of
pBac/Frag-CPRVABC-59 , and (v) the 433 bp StuI-NotI fragment of pRs/30 ROPRVABC-59 .
A total of five bacterial expression plasmids were constructed, each of which was used to express a
32 to 51 aa non-hydrophobic region of the ZIKV polyprotein as a glutathione S-transferase (GST) fusion
protein. In all cases, a defined region of the ZIKV ORF was amplified by PCR using pBac/PRVABC-59
as a template and the appropriate pair of primers listed in Table 2: (i) Frag-zC (147 bp), ZikaC-F
+ ZikaC-R; (ii) Frag-zM (120 bp), ZikaM-F + ZikaM-R; (iii) Frag-zE (147 bp), ZikaE-F + ZikaE-R;
(iv) Frag-zNS4A (177 bp), ZikaNS4A-F + ZikaNS4A-R; and (v) Frag-zNS4B (177 bp), ZikaNS4B-F +
ZikaNS4B-R. Each of the resulting amplicons was cloned into pGex-4T-1 (GE Healthcare, Piscataway,
NJ, USA) by ligating the 4954 bp EcoRI-XhoI fragment of the pGex-4T-1 vector with 135, 108, 135, 165,
and 165 bp EcoRI-XhoI fragments of the Frag-zC, -zM, -zE, -zNS4A, and -zNS4B amplicons, respectively.
This created pGex-zC, -zM, -zE, -zNS4A, and -zNS4B.
2.4. Transcription and Transfection
Infectious transcripts were synthesized from PsrI/BarI-linearized BAC plasmid DNA with SP6
RNA polymerase as described [53] in reactions containing m7 GpppA (New England Biolabs, Ipswich,
MA, USA). RNA integrity was examined by agarose gel electrophoresis. RNA was transfected into
Vero cells by electroporation using the BTX ECM 830 electroporator with a 2-mm-gap cuvette under
optimized conditions (980 V, 99 µs pulse length, and 3 pulses); RNA infectivity was quantified by
infectious center assay [55,56]. The infectious centers of plaques/foci formed on the monolayer of Vero
cells were visualized at 5 days after transfection either nonspecifically by counterstaining of uninfected
cells with crystal violet [55] or specifically by immunostaining of ZIKV-infected cells with rabbit
anti-ZIKV NS1 (α-ZNS1) antiserum and horseradish peroxidase-conjugated goat α-rabbit IgG (Jackson
ImmunoResearch, West Grove, PA, USA), followed by developing with 3,30 -diaminobenzidine [56].
2.5. Growth Kinetics and Cytopathogenicity
Viral growth kinetics and cytopathogenicity were analyzed in 17 animal cell lines from 12 different
species. In each case, naïve cells were seeded into 35 mm culture dishes at a density of 3 × 105 cells/dish
for 12 h, and then mock-infected or infected with viruses at an MOI of 1 for 1 h at 37 ◦ C. Following
incubation, cell monolayers were washed and incubated with complete medium. At 6, 12, 18, 24, 36,
48, 60, 72, and 96 h post-infection (hpi), ZIKV-infected cells were examined morphologically under a
light-inverted microscope (Primo Vert, Carl Zeiss, Jena, Germany) to assess the degree of ZIKV-induced
cytopathic effect (CPE) as compared to mock-infected cells, and culture supernatants were collected to
evaluate the levels of virus production by plaque assays on Vero cells, as described [57]. The infectious
centers of plaques were visualized at 5 days after infection by counterstaining of uninfected cells with
crystal violet [55].
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2.6. Real-Time RT-PCR
ZIKV RNA levels in infected Vero cells were quantified as described [57] by real-time RT-PCR
with the primer pairs and fluorogenic probes listed in Table 2: the ZikaF + ZikaR and ZikaProbe
specific for the ZIKV NS3-coding region that has the identical sequences in all three ZIKVs, and the
VeroF + VeroR and VeroProbe specific for the Vero β-actin coding region. Each ZIKV RNA level was
normalized to the corresponding β-actin mRNA level as an internal control.
2.7. Immunoblotting, Confocal Microscopy, and Flow Cytometry
Individual ZIKV proteins were identified by immunoblotting [31] using each of our six previously
characterized JEV region-specific rabbit antisera that cross-react with their ZIKV counterparts, or seven
newly generated ZIKV region-specific rabbit antisera. The rabbit antibody was detected using alkaline
phosphatase (AP)-conjugated goat α-rabbit IgG (Jackson ImmunoResearch, West Grove, PA, USA),
and the AP enzyme was visualized using colorimetric detection with 5-bromo-4-chloro-3-indolyl
phosphate and nitro blue tetrazolium (Sigma, St. Louis, MO, USA). ZIKV E proteins were visualized by
confocal microscopy [57] with rabbit α-ZE antiserum, followed by secondary labeling with fluorescein
isothiocyanate-conjugated goat α-rabbit IgG (Jackson ImmunoResearch). ZIKV NS4A proteins were
detected by flow cytometry [58] with rabbit α-ZNS4A antiserum, followed by secondary labeling with
Alexa 488-conjugated goat α-rabbit IgG (Invitrogen, Carlsbad, CA, USA).
2.8. Mouse Studies
ZIKV neuropathogenicity was examined in male and female mice of four strains: CD-1 (1, 2,
and 4 weeks, Charles River, Wilmington, MA, USA), C57BL/6J (4 weeks, the Jackson Laboratory, Bar
Harbor, ME, USA), A129 (4 weeks, bred in-house), and AG129 (4 weeks, bred in-house). Groups of
mice were inoculated via the intramuscular (im, 50 µL) or intracerebral (ic, 20 µL) route with 10-fold
serial dilutions of virus stock in α-minimal essential medium and monitored for any ZIKV-induced
clinical signs, weight loss, or death daily for 20 days. The im and ic lethal dose 50% (LD50 ) values for
each virus were calculated from the respective dose-dependent survival curves of the infected mice, as
described [57].
2.9. Ethics Statement
All mouse studies were conducted in strict accordance with the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health, United States of America. The animal protocol
was approved by the Institutional Animal Care and Use Committee (IACUC) of Utah State University
(approved IACUC protocol #2505, 30/03/2016). Discomfort, distress, pain, and injury were minimized
as much as possible through limited handling and euthanization of mice when they were moribund.
3. Results
3.1. Characterization of Three Spatiotemporally Distinct and Genetically Divergent ZIKV Strains
As an initial step in examining the genetic diversity of ZIKV and its biological significance for viral
replication and pathogenesis, we selected three historically important strains of distinct geographical
and temporal origins: (i) MR-766, the first ZIKV identified from the blood of a rhesus macaque
monkey in Uganda in 1947 [1]; (ii) P6-740, the first non-African strain, isolated from a pool of A.
aegypti mosquitoes in Malaysia in 1966 [59]; and (iii) PRVABC-59, the recent American strain recovered
from the blood of a human patient in Puerto Rico in 2015 [60]. To compare the genome sequence and
composition of these three ZIKVs, we determined the consensus nucleotide sequence for each of their
full-length genomic RNAs [54]. In all three strains of ZIKV, we found that the genomic RNA is 10,807
nt long, with a single ORF of 10,272 nt flanked by a 106 or 107 nt 50 NCR and a 428 or 429 nt 30 NCR
(Figure 1A). Also, the three genomic RNAs all begin with the dinucleotide 50 -AG and end with the

agreement with previous ORF-based phylogenetic studies that classified 10–40 ZIKV isolates into two
major genetic lineages, African and Asian [40–42]. The African lineage branches into two clusters, one
including four different versions of the Ugandan MR-766 strain (1947) that are not identical in genome
sequence, mainly because of a variation in the passage history of the virus, and the other including
the three Senegalese isolates 41671-DAK, 41525-DAK, and 41662-DAK, all isolated in 1984. On the
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The
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spatiotemporally distinct strains: MR-766, P6-740, and PRVABC-59. The consensus nucleotide sequence
for each of their full-length genomic RNAs was determined by sequencing three overlapping uncloned
cDNA amplicons collectively representing the entire genomic RNA, except for the 50 and 30 termini,
which were subsequently defined by performing both 50 - and 30 -rapid amplification of cDNA ends
(RACE); each of these RACEs was followed by cDNA cloning and sequencing of ~20 randomly
picked clones. (A) Genomic organization of the three ZIKV strains; (B) Pairwise comparison of the
complete nucleotide (nt) and deduced amino acid (aa) sequences of the three ZIKV genomes; (C)
Phylogenetic tree based on the nucleotide sequence of 29 ZIKV genomes, including the 15 complete
(MR-766, green; P6-740, orange; PRVABC-59, red; and 12 others, black) and 14 near-complete (gray)
genomes, with Japanese encephalitis virus (JEV) K87P39 included as an outgroup. Bootstrap values
from 1000 replicates are shown at each node of the tree. The scale bar represents the number of
nucleotide substitutions per site. The strain name is followed by a description in parenthesis of the
country, year, and host of isolation and the GenBank accession numbers. Note that MR-766 has been
fully sequenced in this study and by three other groups (designated MR-766/CDC, MR-766/NIID,
and MR-766/USAMRIID).

To examine the genetic relationship between the three spatiotemporally distinct ZIKVs and their
associations with other strains, we performed a multiple sequence alignment for phylogenetic analysis
using the nucleotide sequence of all 29 ZIKV genomes (15 complete, 14 near-complete) in GenBank at
the time of analysis (June 2016), including our complete nucleotide sequence of the genomes of MR-766,
P6-740, and PRVABC-59. Construction of a genome-based rooted phylogenetic tree using JEV K87P39
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as an outgroup revealed two distinct phylogenetic groups (Figure 1C), in agreement with previous
ORF-based phylogenetic studies that classified 10–40 ZIKV isolates into two major genetic lineages,
African and Asian [40–42]. The African lineage branches into two clusters, one including four different
versions of the Ugandan MR-766 strain (1947) that are not identical in genome sequence, mainly
because of a variation in the passage history of the virus, and the other including the three Senegalese
isolates 41671-DAK, 41525-DAK, and 41662-DAK, all isolated in 1984. On the other hand, the Asian
lineage contains a single cluster of the Malaysian P6-740 (1966), Cambodian FSS13025 (2010), Philippine
CPC-0740 (2012), and Thai SV0127-14 (2014) strains, as well as 18 other isolates collected during the
2015–2016 American epidemic, including the Puerto Rican PRVABC-59 strain (2015). Notably, the four
pre-epidemic Asian strains (P6-740, FSS13025, CPC-0740, and SV0127-14) are closely related to the
2015–2016 American epidemic strains, but each forms a single minor branch. Overall, our data indicate
that MR-766 belongs to the African lineage, whereas both P6-740 and PRVABC-59 belong to the Asian
lineage, with PRVABC-59 being derived from an ancestor of the Asian lineage.
3.2. Development of Genetically Stable Full-Length Infectious cDNA Clones for the Three ZIKV Strains
We constructed three full-length infectious ZIKV cDNAs for the MR-766, P6-740, and PRVABC-59
strains, each capable of serving as a template for the rescue of molecularly cloned ZIKVs (Figure 2).
In each strain, five overlapping cDNA fragments representing the 10,807 nt genomic RNA were
sequentially assembled into a full-length cDNA in the single-copy BAC vector pBeloBAC11, in order
to ensure the stable maintenance of the cloned cDNA during propagation in Escherichia coli,
with an SP6 promoter sequence positioned immediately upstream of the viral 50 -end and a unique
restriction endonuclease recognition site (PsrI for MR-766, BarI for P6-740 and PRVABC-59) placed
just downstream of the viral 30 -end. Both the SP6 promoter and the unique restriction site were
engineered so that in vitro run-off transcription could be used to produce m7 G-capped synthetic RNAs
bearing authentic 50 and 30 ends of the viral genomic RNA. Using this BAC-based cloning strategy,
we thus created a panel of three full-length ZIKV cDNAs, designated pBac/MR-766, pBac/P6-740,
and pBac/PRVABC-59 (Figure 2A).
To evaluate the functionality of the three full-length ZIKV BACs, we determined the viability of
the synthetic RNAs transcribed in vitro from each BAC by measuring their specific infectivity after
RNA transfection into a ZIKV-susceptible African green monkey kidney (Vero) cell line. To prepare a
DNA template for in vitro run-off transcription, the three full-length ZIKV BACs were first linearized
by digestion with PsrI (for pBac/MR-766) or BarI (for pBac/P6-740 and pBac/PRVABC-59). Each was
then used as a template for a run-off transcription reaction using SP6 RNA polymerase in the
presence of the m7 GpppA cap structure analog. After removal of the DNA template by DNase I
digestion, we transfected Vero cells with the RNA transcripts, quantifying their infectivity as the
number of plaque-forming units (PFU) per µg of transfected RNA. In all three BACs, the RNA
transcripts invariably had a high infectivity of 8.1–8.6 × 105 PFU/µg and were capable of producing
a high-titer stock of infectious ZIKVs in culture medium that reached 1.3–5.0 × 106 PFU/mL at 36 h
after transfection (Figure 2B). Each of the three recombinant BAC-derived ZIKVs (designated by
the prefix “r”) formed a homogeneous population of plaques that differed from the others in size,
with mean diameters of 5.7 (rMR-766), 1.6 (rP6-740), and 5.2 (rPRVABC-59) mm (Figure 2C). We also
demonstrated that using pBac/P6-740, the infectivity of its RNA transcripts was decreased by ~4 logs
to a barely detectable level (55–105 PFU/µg), with a single C9804 →U substitution (an unintended
mutation introduced during the overlapping cDNA synthesis by RT-PCR) replacing a His with Tyr
at position 713 of the viral NS5 protein (Figure S1A,B). On the crystal structure of ZIKV NS5 [61,62],
the His-713 residue is located within the conserved structural motif E region near the priming loop in
the RNA-dependent RNA polymerase domain (Figure S1C), suggesting a critical role for His-713 in
the polymerase function of ZIKV NS5.
Next, we examined the genetic stability of the three full-length ZIKV BACs that are important
for reliable and efficient recovery of infectious viruses from the cloned cDNAs. A single colony of
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E. coli DH10B carrying each of the three full-length ZIKV BACs was grown in liquid medium and
serially passaged for 4 days by diluting it 106 -fold daily, such that each passage represented ~20
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3.3. Differential Replication Kinetics and Cytopathogenicity among Three Molecularly Cloned ZIKVs in
Human, Mosquito, and Animal Cell Lines
To test whether the genetic variation in ZIKV can have differential effects on its replication kinetics
and cytopathogenicity, we infected monkey kidney-derived Vero cells at an MOI of 1, then examined
the replicative and cytopathic properties of the three cloned cDNA-derived ZIKVs (rMR-766, rP6-740,
and rPRVABC-59) as compared to those of the uncloned parental ZIKVs (MR-766, P6-740, and
PRVABC-59) used for cDNA construction. In all three strains, we saw no noticeable differences
between the cloned and uncloned viruses in the accumulation of viral genomic RNA over the first
24 hpi (Figure 3A), paralleling not only the kinetics of viral growth and CPE development over the
first 3 days post-infection (Figure 3B) but also the average sizes of the α-ZNS1 antibody-reactive
foci immunostained at 5 days post-infection (Figure 3C). However, we did observe clear differences
between the three strains, regardless of whether they were cloned or uncloned viruses, with respect to
their replication kinetics and cytopathogenicity (Figure 3A–C). Our specific findings are as follows:
(i) rMR-766/MR-766 displayed the fastest rate of RNA replication, induced complete lysis of the
infected cells by 36 hpi, achieved the highest virus titer of 2.0–3.3 × 107 PFU/mL at 36–48 hpi, and
formed the largest foci of 6.3 mm diameter. (ii) rP6-740/P6-740 had the slowest rate of RNA replication,
did not cause complete CPE until 72 hpi, reached its maximal virus titer of 1.1–1.2 × 107 PFU/mL at
60–72 hpi, and generated the smallest foci of 2.4 mm diameter. (iii) rPRVABC-59/PRVABC-59 had a rate
of RNA replication slightly slower than rMR-766/MR-766 but much faster than that of rP6-740/P6-740;
it caused complete CPE by 48 hpi, with a peak virus titer of 0.9–1.4 × 107 PFU/mL at 36–48 hpi, and
produced foci of 5.9 mm diameter.
We further analyzed the replicative and cytopathic potential of the three cDNA-derived ZIKVs
in 16 other animal cell lines from 11 different species, over the first 4 days after infection of the cells
with each virus at an MOI of 1. Our data revealed seven distinct patterns of viral growth kinetics
and cytopathogenesis, depending on a combination of the viral strain and host cell line (Figure 3D
and Figure S3): (1) In all three human cell types (embryonic kidney HEK, hepatocarcinoma Huh-7,
and neuroblastoma SH-SY5Y), rMR-766 and rP6-740 grew equally well, to maximum titers of 107 –108
PFU/mL at 48–72 hpi, but rPRVABC-59 always grew at a slower rate, attaining a peak titer 1–2 logs
lower than that of the other two strains at 72–96 hpi (HEK and SH-SY5Y) or reaching a peak titer
similar to that of the other two strains only at 96 hpi (Huh-7); all three ZIKVs induced cell death, with a
correlation between the degree of CPE and the magnitude of viral replication. (2) In swine testis (ST)
and equine skin (NBL-6) cells, the three ZIKVs replicated to their peak titers of 106 –107 PFU/mL at
48 hpi, with differential growth rates similar to those seen in Vero cells (rMR-766, fastest; rP6-740,
slowest; rPRVABC-59, intermediate) that paralleled the kinetics of CPE development. (3) In sheep fetal
fibroblast (SFF-6) and A. albopictus (C6/36) cells, the three ZIKVs shared a superimposable growth
curve, characterized by a steady increase in virus titers up to ~107 PFU/mL by 96 hpi, except for rP6-740,
which had an exponential growth during 24–48 hpi in C6/36, but not SFF-6 cells. None of the three
ZIKVs produced any visible CPE. (4) In goat fetal fibroblast (GFF-4), canine kidney (MDCK), and feline
kidney (CRFK) cells and in all three mouse cell types (C57BL/6-derived embryonic fibroblast MEF,
NIH/Swiss-derived embryonic fibroblast NIH/3T3, and motor neuron-like hybrid NSC-34), rMR-766
was the fastest-growing, reaching its highest titer of 106 –107 PFU/mL at 48–96 hpi; rPRVABC-59 was
the slowest-growing, gaining a maximum titer of only 103 –104 PFU/mL during the same period;
and rP6-740 was intermediate in growth rate. However, none of these viruses produced visible CPE.
(5) In chicken embryo fibroblast (CEF) cells, both rMR-766 and rP6-740 had a relatively long lag period
of 36 h, followed by a gradual increase in virus titer up to 105 –106 PFU/mL by 96 hpi; in contrast,
rPRVABC-59 grew extremely poorly, resulting in a slow decrease in virus titer to 45 PFU/mL by
96 hpi. No CPE was observed for any of the three ZIKV-infected CEF cells. (6) In bovine turbinate (BT)
cells, the three ZIKVs showed substantial differences in growth kinetics, reaching a plateau at 96 hpi,
with peak titers of 4.4 × 105 (rMR-766), 5.0 × 104 (rPRVABC-59), and 8.8 × 102 (rP6-740) PFU/mL.
However, no visible CPE was induced in any of the ZIKV-infected cells. (7) In bovine kidney (MDBK)
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cells, the titers of all three ZIKVs declined to undetectable levels at 60–96 hpi, with no overt signs of
viral replication.
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general defect in the clathrin-dependent endocytic pathway that ZIKV utilizes for internalization [63].
We thus investigated the functional integrity of the clathrin-dependent endocytic pathway in MDBK
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cross-reactivity with their ZIKV counterparts, given the relatively high levels (35–71%) of amino acid
sequence identity between their antigenic regions (Figure 5A). Indeed, six (α-JEN-term , α-JNS1C-term ,
α-JNS2B, α-JNS3C-term , α-JNS5N-term , and α-JNS5C-term ) of the 15 antisera showed moderate-to-strong
cross-reactivity with their respective ZIKV gene products, but the remaining nine had no reactivity
(Figure 5B). To cover the remaining undetected parts of ZIKV ORF, we then generated seven ZIKV
region-specific rabbit antisera, using rPRVABC-59 as the viral strain of choice, immunizing the rabbits
with five bacterially expressed GST fusion proteins (α-ZC, α-ZM, α-ZE, α-ZNS4A, and α-ZNS4B) or
two chemically synthesized oligopeptides (α-ZNS1 and α-ZNS2B) (Figure S6A,B). In all cases, the 19
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as a loading and transfer control. Molecular size markers are given on the left of each blot, and major
JEV proteins for reference are labeled on the right. Provided below each blot are the estimated
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Our immunoblot analysis using a collection of 13 ZIKV antigen-reactive region-specific rabbit
antisera allowed us to create a full catalog of viral gene products and their related species, except
for the predicted 24 kDa NS2A (Figures 5 and 6): (1) α-ZC recognized the 13 kDa C protein, with no
accumulation of the further-processed 12 kDa C’ (see below for description of virion-associated
proteins), but with appearance of one or two cleavage products of 10–11 kDa in rPRVABC-59- or
rP6-740-infected cells, respectively; however, this antiserum did not react with any of the C-related
proteins of rMR-766. (2) α-ZM reacted strongly with the 9 kDa M protein and its 24 kDa precursor
prM, with the ratio of M:prM varying in the presence of equal amounts of the loading control GAPDH
protein, depending on the viral strain; the observed size of prM was 5 kDa larger than its predicted
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size, consistent with an addition of N-glycans at Asn-70 (70 NTT) to its pr domain [64] that is conserved
in all three ZIKVs. Also, the α-ZM reacted weakly with at least two minor proteins of 15 and 19
kDa. (3) α-JEN-term /α-ZE detected four E-related proteins (of 54/56, 43/45, 24/26, and 14 kDa).
Among these, the first three proteins from rP6-740 were all 2 kDa smaller than those from rMR-766
and rPRVABC-59, in agreement with a missense mutation of the N-glycosylation site at Asn-154
(154 NDT→NDI) in the E protein of rP6-740 relative to that of rMR-766 and rPRVABC-59 [19,20]. Indeed,
the three 2 kDa smaller proteins from rP6-740 became similar in size to those from rMR-766 and
rPRVABC-59, when the mutated N-glycosylation motif in rP6-740 was restored by changing 154 NDI
into 154 NDT, but not by changing 154 NDI into 154 QDT (Figure S7A–C). (4) Both α-JNS1C-term and
α-ZNS1 identified the 45 kDa NS1 exclusively. This protein was 5 kDa larger than predicted by its
amino acid sequence because of the addition of N-glycans at Asn-130 (130 NNS) and Asn-207 (207 NDT),
both of which are conserved in all three ZIKVs [65,66]. As expected, these data also showed that only
NS1, and not its frameshift product NS1’, was produced by all three ZIKVs. (5) α-JNS2B/α-ZNS2B
revealed the 14 kDa NS2B, together with a minor protein of 11 kDa at a barely detectable level.
(6) α-JNS3C-term recognized the 69 kDa NS3; it also reacted more strongly with a major cleavage
product of 34 kDa, representing the C-terminal half of the full-length NS3 [31], and less intensely
with at least seven minor proteins of 33–60 kDa. Intriguingly, α-JNS3C-term detected a species with
a mass of 85 kDa, corresponding to the calculated size of an NS2B-3 or NS3-4A/4A’ processing
intermediate. (7) α-ZNS4A did not detect the predicted 16 kDa NS4A, but did predominantly recognize
its further-processed 14 kDa NS4A’, which ran as a single species in tricine–SDS-PAGE but migrated as
a doublet in glycine–SDS-PAGE. Unexpectedly, this antiserum also identified two clusters of multiple
protein bands, one at 29 kDa (NS4Ap29 ) and the other at 35 kDa (NS4ABp35 , which also reacted with
α-ZNS4B; Figure S8A,B). (8) α-ZNS4B stained the predicted major 27 kDa NS4B, along with two minor
proteins at 11 kDa (NS4Bp11 ) and 35 kDa (NS4ABp35 , which again reacted with α-ZNS4A; Figures
S8A,B). (9) α-JNS5N-term and α-JNS5C-term reacted with the predicted 103 kDa NS5.
In addition to the three full-length structural proteins (C, prM/M, and E) of ZIKV, their multiple
smaller products were accumulated to lower but still significant amounts in Vero cells infected with
each of the three ZIKVs, with nearly the same protein expression profile (Figure 6). To define the
actual viral structural proteins incorporated into ZIKV particles, rPRVABC-59 was used to profile
all the structural proteins associated with extracellular virions, which were purified by pelleting
through a 20% sucrose cushion. We then compared them with their cell-associated counterparts by
immunoblotting with α-ZC, α-ZM, and α-ZE (Figure 7). The purified ZIKV particles were shown
to contain (i) the 12 kDa C’ protein, which appeared as a closely spaced doublet with the lower
band being more prominent than the upper band and migrating in a gel marginally faster than
one cell-associated major 13 kDa C protein, but slower than the other cell-associated minor 10 kDa
C-derived cleavage product; (ii) the 9 kDa M protein and a trace amount of its glycosylated precursor
prM, which appeared as two bands, the slightly less intense and faster one migrating with a mass of
23–24 kDa and the slightly more intense and slower one at 25–26 kDa, reflecting the trimming of high
mannose and the addition of more complex sugars to the cell-associated 24 kDa prM protein during
virus release through the cellular secretory pathway [67]; and (iii) the glycosylated 58 kDa E protein,
which ran slightly slower than the cell-associated 56 kDa E protein, again reflecting the difference in its
glycosylation status. Collectively, we have demonstrated that the extracellular ZIKVs are composed of
three post-translationally modified full-length structural proteins, excluding their smaller species.

Viruses 2018, 10, x FOR PEER REVIEW

composed
Viruses
2018, 10,of422three
smaller species.

17 of 28

post-translationally modified full-length structural proteins, excluding17 their
of 28

Figure7.
7. Profiling
Profiling of
of virion-associated
virion-associated ZIKV
ZIKV proteins
proteins compared
compared to
to their
their cell-associated
cell-associated counterparts.
counterparts.
Figure
Vero
Verocells
cellswere
wereleft
leftuninfected
uninfected(Uninf)
(Uninf)or
orinfected
infected(Inf)
(Inf)with
withZIKV
ZIKV rPRVABC-59
rPRVABC-59atatan
anMOI
MOIof
of1.1.For
For
cell-associated
cell-associated viral
viral proteins,
proteins, total
total cell
cell lysates
lysates were
were prepared
prepared by
by lysing
lysing the
the cell
cell monolayers
monolayers at
at 20
20 hh
post-infection.
For virion-associated
post-infection. For
virion-associated viral
viral proteins,
proteins, cell
cell culture
culture supernatants
supernatants were
were collected
collected at
at the
the
same
sametime
timepoint,
point,and
and extracellular
extracellularvirions
virionswere
werepelleted
pelletedby
byultracentrifugation
ultracentrifugationthrough
throughaa20%
20%sucrose
sucrose
cushion.
byby
SDS-PAGE
onon
a
cushion.Equivalent
Equivalentportions
portionsofoftotal
totalcell
celllysates
lysatesand
andpelleted
pelletedvirions
virionswere
wereresolved
resolved
SDS-PAGE
glycine
(Gly)
or tricine
(Tri) gel
andgel
analyzed
by immunoblotting
with α-ZC,
α-ZM,
a glycine
(Gly)
or tricine
(Tri)
and analyzed
by immunoblotting
with
α-Zor
C,α-ZE.
α-ZM,Molecular
or α-ZE.
weight
markers
aremarkers
shown on
left ofon
each
The
molecular
of predicted
C, predicted
C’, prM, M,
Molecular
weight
arethe
shown
the blot.
left of
each
blot. Theweights
molecular
weights of
C,
and
E
proteins
are
indicated
below
each
blot.
Marked
on
each
blot
are
the
predicted
proteins
(yellow
or
C’, prM, M, and E proteins are indicated below each blot. Marked on each blot are the predicted
pink
dot) (yellow
and presumed
cleavage/degradation
(white circle). products
CHO, N-glycosylation.
proteins
or pinkfurther
dot) and
presumed further products
cleavage/degradation
(white circle).
CHO, N-glycosylation.

3.5. Wide Range of Differences in Age-Dependent Neuropathogenicity among Three Molecularly Cloned ZIKVs
in
Outbred
CD-1 of
Mice
3.5.
Wide Range
Differences in Age-Dependent Neuropathogenicity among Three Molecularly Cloned
ZIKVs
Outbred CD-1
Mice
Weincompared
the virulence
of rMR-766, rP6-740, and rPRVABC-59 in CD-1 mice at three different
ages We
(1, 2,
and 4 weeks)
by examining
two neuropathogenic
properties: in
(i) CD-1
neuroinvasiveness
compared
the virulence
of rMR-766,
rP6-740, and rPRVABC-59
mice at three
(the
ability ages
to penetrate
central
nervous by
system
from a peripheral
site), quantified properties:
by generating
different
(1, 2, the
and
4 weeks)
examining
two neuropathogenic
(i)
the
dose-dependent(the
survival
and determining
thenervous
LD50 after
an im
inoculation;
andsite),
(ii)
neuroinvasiveness
abilitycurve
to penetrate
the central
system
from
a peripheral
neurovirulence
(the ability the
to establish
a lethal infection
nervousthe
system),
quantified
quantified by generating
dose-dependent
survivalwithin
curve the
andcentral
determining
LD50 after
an im
by
creating theand
dose-dependent
survival(the
curve
and measuring
theaLD
an ic inoculation.
both
inoculation;
(ii) neurovirulence
ability
to establish
lethal
infection
within theFor
central
50 after
im
and ic system),
inoculations,
we firstby
determined
thedose-dependent
appropriate dosesurvival
ranges for
calculating
the LD50the
values,
nervous
quantified
creating the
curve
and measuring
LD50
and
we
optimized
the
study
designs
prior
to
the
performance
of
full-scale
experiments.
For
these
after an ic inoculation. For both im and ic inoculations, we first determined the appropriate dose
pilot
experiments,
we injected
threeand
age we
groups
of the the
mice
withdesigns
a maximum
each virus:
ranges
for calculating
the LD50 all
values,
optimized
study
prior dose
to theofperformance
5 PFU/mouse for im inoculations and 3.6 × 104 PFU/mouse for ic inoculations. If necessary,
1.2
×
10
of full-scale experiments. For these pilot experiments, we injected all three age groups of the mice
5 PFU/mouse for
we
then
performed
a series
ofvirus:
large-scale
dose-response
studies,
inoculating
groups
of4 the
mice at
with
a maximum
dose
of each
1.2 × 10
im inoculations
and
3.6 × 10
PFU/mouse
1,
and
4 weeks of If
age
via the im
ic route
with serial
10-fold
dilutions ofdose-response
the virus. Following
for2, ic
inoculations.
necessary,
weorthen
performed
a series
of large-scale
studies,
infection,
the
mice
were
monitored
daily
for
mortality,
weight
loss,
and
other
clinical
signs
of
illness
inoculating groups of the mice at 1, 2, and 4 weeks of age via the im or ic route with serial 10-fold
over
20 days.
dilutions
of the virus. Following infection, the mice were monitored daily for mortality, weight loss,
assessments
of our
survival curves and LD50 values revealed the
and The
othercomparative
clinical signs
of illness over
20dose-dependent
days.
following
(Figure
8A):
(i)
rMR-766
exhibited
age-dependent
evidenced
an im
The comparative assessments of our dose-dependent neuroinvasiveness,
survival curves andasLD
50 values by
revealed
5
LD
of 90.2 PFU
for 1-week-old
mice and
>1.2 × 10
PFU for 2- and
4-week-old mice, as
yetevidenced
it displayed
the50following
(Figure
8A): (i) rMR-766
exhibited
age-dependent
neuroinvasiveness,
by
aanhigh
at all threemice
ages,and
as evidenced
by anfor
ic 2LDand
of
<3.6,
3.6,
and
5.7
PFU
im level
LD50 of
of neurovirulence
90.2 PFU for 1-week-old
>1.2 × 105 PFU
4-week-old
mice,
yet
it
50
for
1-, 2-, and
4-week-old
respectively.
(ii)three
rP6-740
showed
barely detectable
neuroinvasiveness
displayed
a high
level of mice,
neurovirulence
at all
ages,
as evidenced
by an ic LD
50 of <3.6, 3.6, and
in
1 or 3 of 10
infected
mice dying(ii)
when
inoculated
with
the two
highest
5.71-week-old
PFU for mice,
1-, 2-,with
andonly
4-week-old
mice,
respectively.
rP6-740
showed
barely
detectable
3 or 3.6 × 104 PFU/mouse, respectively (im LD , >3.6 × 104 PFU). Similarly, it had
doses,
3.6
×
10
neuroinvasiveness in 1-week-old mice, with only 1 or 3 of 10 infected
mice dying when inoculated
50
3 or
no
detectable
and
mice, with
no infected
mice
with
the two neuroinvasiveness
highest doses, 3.6 ×in1023.64-week-old
× 104 PFU/mouse,
respectively
(im
LD50dying
, >3.6 even
× 104 when
PFU).
5
5
inoculated
with
dose,neuroinvasiveness
1.2 × 10 PFU/mouse
,
>1.2
×
10
PFU).
However,
rP6-740
Similarly, it
hadthe
nohighest
detectable
in 2- (im
andLD
4-week-old
mice,
with
no
infected
mice
50
5
5
showed
age-dependent
neurovirulence,
as
it
was
highly
neurovirulent
in
1-week-old
mice
(ic
LD
dying even when inoculated with the highest dose, 1.2 × 10 PFU/mouse (im LD50, >1.2 × 10 PFU).
50 ,
4
<3.6
PFU) but
non-neurovirulent
in 2- and 4-week-old
mice (icasLD
, >3.6
× 10neurovirulent
PFU). (iii) rPRVABC-59
However,
rP6-740
showed age-dependent
neurovirulence,
it 50
was
highly
in 1-weekwas essentially non-neuroinvasive and non-neurovirulent, regardless of the mouse age, with its im and

Viruses 2018, 10, 422
Viruses 2018, 10, x FOR PEER REVIEW

18 of 28
18 of 28

ic LD50 values estimated to be greater than the highest dose used for each route of infection, without
old mice
LD50three
, <3.6 PFU)
but non-neurovirulent
in 2- and
4-week-old
mice
(ic LD50, >3.6
× 104 PFU). was the
a single death.
Of(icthe
ZIKVs,
therefore, rMR-766
was
the most
virulent,
rPRVABC-59
(iii) rPRVABC-59 was essentially non-neuroinvasive and non-neurovirulent, regardless of the mouse
least virulent,
and rP6-740 showed intermediate virulence. The observed differences in virulence are
age, with its im and ic LD50 values estimated to be greater than the highest dose used for each route
correlatedofwith
the variations
in viral
passage
history
in therefore,
mice (Figure
1A).
infection,
without a single
death.
Of the three
ZIKVs,
rMR-766
was the most virulent,
Moreover,
we
recognized
not
only
the
lethal
virulence
displayed
by
rMR-766The
and
rP6-740 but also
rPRVABC-59 was the least virulent, and rP6-740 showed intermediate virulence.
observed
differences
in
virulence
are
correlated
with
the
variations
in
viral
passage
history
in
mice
(Figure
1A).effect was
the non-lethal virulence exhibited by all of the three ZIKVs, including rPRVABC-59. This
Moreover, we recognized not only the lethal virulence displayed by rMR-766 and rP6-740 but
most prominent in 1-week-old mice (Figure 8B). The lethal virulence was invariably associated with a
also the non-lethal virulence exhibited by all of the three ZIKVs, including rPRVABC-59. This effect
sharp dropwas
in most
the body
weight
of infected
that
began
~3 days
prior
death, inassociated
conjunction with
prominent
in 1-week-old
micemice
(Figure
8B).
The lethal
virulence
wastoinvariably
clinical signs.
began
with
decreased
activity,
ruffled
fur,began
and~3
hunched
and
often progressed
with It
a sharp
drop
in the
body weight
of infected
mice that
days priorposture,
to death, in
conjunction
signs. paralysis.
It began with
decreased
activity,
and hunched
posture, in
andthe
often
to tremorswith
andclinical
hind limb
Various
viral
loadsruffled
werefur,
detected
postmortem
brains of all
progressed to tremors
and hind
limb paralysis. Various viral loads were detected postmortem in the
3
8
mice that died (8.0 × 10 –3.9 × 10 PFU/brain).
Non-lethal virulence, in contrast, was characterized
brains of all mice that died (8.0 × 103–3.9 × 108 PFU/brain). Non-lethal virulence, in contrast, was
by an initial
weight
loss
of
various
degrees,
albeit
without
obvious
clinicalclinical
signs,signs,
andand
a subsequent
characterized by an initial weight loss of various degrees,
albeit
without obvious
a
recovery, to
some
extent,
that
was
not
complete.
At
the
end
of
the
study,
no
infectious
subsequent recovery, to some extent, that was not complete. At the end of the study, no infectiousZIKV was
detected
in the
brains
of any
of survived.
the mice thatInsurvived.
both the
lethal
and non-lethal
detected inZIKV
the was
brains
of any
of the
mice
that
both theInlethal
and
non-lethal
virulent cases,
virulent cases, no changes in body temperature were observed. Altogether, we found that in CD-1
no changes in body temperature were observed. Altogether, we found that in CD-1 mice, the three
mice, the three ZIKVs had a wide range of virulence, depending on the virus strain, mouse age, and
ZIKVs hadroute
a wide
range of virulence, depending on the virus strain, mouse age, and route of infection.
of infection.

Figure 8. Three molecularly cloned ZIKVs display a full range of variation in neuropathogenicity for

Figure 8. Three molecularly cloned ZIKVs display a full range of variation in neuropathogenicity
outbred CD-1 mice in an age-dependent manner. Groups of CD-1 mice (n = 8–10, half male, half
for outbred
CD-1
mice
in an age-dependent
of via
CD-1
mice (n = 8–10,
female)
were
mock-inoculated
or inoculated atmanner.
1, 2, and 4 Groups
weeks of age
the intramuscular
(im) or half male,
intracerebral
(ic) route with a maximum
dose ofat
3.61,× 2,
104and
or 1.2
105 PFU,
serial
dilutions
half female)
were mock-inoculated
or inoculated
4 ×weeks
oforage
via10-fold
the intramuscular
(im)
of rMR-766,
rP6-740,
or arPRVABC-59.
(A) Survival
curves
were
by the
Kaplan–Meier
or intracerebral
(ic) route
with
maximum dose
of 3.6 ×
104 or
1.2generated
× 105 PFU,
or serial
10-fold dilutions
method, and LD50 values were determined by the Reed–Muench method and are presented in the
of rMR-766, rP6-740, or rPRVABC-59. (A) Survival curves were generated by the Kaplan–Meier method,
bottom left corner of each curve. (B) Weight changes are plotted, with each mouse represented by one
and LD50 color-coded
values were
by the Reed–Muench method and are presented in the bottom left
line.determined
dpi, days post-infection.
corner of each curve. (B) Weight changes are plotted, with each mouse represented by one color-coded
line. dpi, days post-infection.

3.6. High Degree of Variation in Interferon (IFN) Sensitivity among Three Molecularly Cloned ZIKVs in Mice
Lacking Type I (IFNAR−/− ) or Both Type I and II IFN (IFNAR−/− /IFNGR−/− ) Receptors
To compare the contributions of the host IFN response to the virulence of rMR-766, rP6-740,
and rPRVABC-59, we examined their neuroinvasiveness and neurovirulence by using groups
of 4-week-old A129 (IFNAR−/− ) mice and groups of age-matched wild-type inbred C57BL/6J
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mice as a control (Figure 9A). In the control mice, rMR-766 was non-neuroinvasive (im LD50 ,
>1.2 × 105 PFU)
but neurovirulent (ic LD50 , 7.8 PFU). In contrast, both rP6-740 and
rPRVABC-59
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Figure 9. Three molecularly cloned ZIKVs show a full spectrum of variation in IFN sensitivity in mice
lacking type I or both type I and II IFN receptors. Groups of 4-week-old C57BL/6J (n = 8), A129 (n = 5),
or AG129 (n = 5) mice, approximately half of each sex, were mock-inoculated or inoculated through
the intramuscular (im) or intracerebral (ic) route with a maximum dose of 3.6 × 104 or 1.2 × 105 PFU,
or serial 10-fold dilutions of rMR-766, rP6-740, or rPRVABC-59. (A) Survival curves were created by the
Kaplan–Meier method, and LD50 values were calculated by the Reed–Muench method and are given
in the bottom left corner of each curve; (B) Weight changes are plotted, with each mouse indicated by
one color-coded line. NT, not tested; dpi, days post-infection.
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4. Discussion
Here, we report the first development of three full-length infectious ZIKV cDNAs as BACs for
each of three spatiotemporally distinct and genetically divergent ZIKV strains [54]: MR-766 (Uganda,
1947), P6-740 (Malaysia, 1966), and PRVABC-59 (Puerto Rico, 2015). We have also produced 13 ZIKV
region-specific polyclonal rabbit antisera capable of identifying all the viral structural and nonstructural
proteins and their related species, except for NS2A. Using our functional cDNAs and antibodies in
combination with various cell culture and murine model systems, we have demonstrated that the
three molecularly cloned cDNA-derived ZIKVs have the nearly same genome-wide viral protein
expression profile but differ in their replication kinetics and neuropathogenicity (neuroinvasiveness
and neurovirulence), depending on the particular combination of viral and host genetic backgrounds,
as well as in the presence or absence of type I/II IFN signaling. In particular, our results demonstrate
that type I IFN regulates ZIKV neuroinvasiveness in a virus strain-dependent manner. In all, these
reagents offer a new toolbox for viral genome engineering and protein analysis. Together with a roster
of in vitro and in vivo infection models, these tools will not only provide an ideal platform for defining
the viral and host genetic factors that contribute to ZIKV replication and pathogenesis at the cellular
and organismic levels, but also offer promising new avenues for developing and testing an effective,
critically needed vaccine against ZIKV.
The advent of functional cDNA-based reverse genetics has revamped the field of RNA viruses [68].
For flaviviruses, however, the cloned cDNAs are commonly unstable because of the toxicity of their
prM-E genes in host cells, posing a major technical challenge to functional cDNA construction [69].
In the present study, we cloned a complete cDNA copy of the ZIKV genomic RNA into a BAC vector
that is capable of stably housing a DNA fragment of >300 kb in bacteria [70], as we have already
done for JEV [53,58]. In the case of all three ZIKVs (MR-766, P6-740, and PRVABC-59), we showed
that the structural and functional integrity of their full-length BACs remained stable for at least 80
generations of growth in E. coli. To date, the BAC cloning technology has been applied to constructing
full-length infectious cDNAs for ~10 members of three plus-strand RNA virus families (Flaviviridae,
Arteriviridae, and Coronaviridae), all of which have a large genome size of 11–31 kb [52]. Moreover, we
performed site-directed mutagenesis to introduce a point mutation(s) into the full-length infectious
cDNA BAC clone of ZIKV P6-740, which demonstrated (i) the functional importance of His-713 within
the conserved structural motif E region in the RNA-dependent RNA polymerase domain of ZIKV NS5
for viral RNA replication and (ii) the functional significance of the N-glycosylation site at Asn-154 in
the viral E protein for its biogenesis. These results indicate that targeted mutations can be engineered
by manipulating the infectious ZIKV BACs in E. coli. Thus, our BAC-based reverse genetics for ZIKV
will facilitate genetic studies of both viral RNA elements and gene products associated with all aspects
of ZIKV biology.
We formulated a strategy to assemble three full-length infectious ZIKV cDNAs, each capable of
generating m7 G-capped in vitro-transcribed RNAs identical in nucleotide sequence to their respective
genomic RNAs, particularly regarding the 50 - and 30 -end sequences. On the 50 side, we positioned an
SP6 promoter sequence (50 -ATTTAGGGGACACTATAG, with transcription starting at the underlined
G) upstream of the first adenine nucleotide of the viral genome to incorporate the dinucleotide cap
analog m7 GpppA in SP6 RNA polymerase-driven in vitro transcription reactions. The importance
of an m7 G cap at the 50 -end of transcribed RNAs in maximizing RNA infectivity was shown by our
finding that uncapped RNAs derived from each of the three functional ZIKV cDNAs always had
an infectivity >3-logs lower than that of their m7 G-capped counterparts. On the 30 side, we placed
a unique restriction endonuclease recognition site, PsrI [(N7 ↓N12 )GAACN6 TAC(N12 ↓N7 )] or BarI
[(N7 ↓N12 )GAAGN6 TAC(N12 ↓N7 )], downstream of the last thymine nucleotide of the viral genome.
The use of PsrI/BarI for cDNA linearization is particularly advantageous because both are extremely
rare-cutting endonucleases that cut out their recognition sequences after any nucleotide, which makes
this approach applicable for all plus-strand RNA viruses, regardless of the identity of the nucleotide at
the 30 end of the viral genome. We found that RNA transcripts with 11 ZIKV-unrelated nucleotides
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hanging on their 30 ends were ~1-log less infectious than those with authentic 30 ends, indicating the
importance of the authentic 30 end for the production of infectious ZIKV RNAs.
Several functional cDNAs for ZIKV have hitherto been made using two different strategies,
depending on the vector adopted to clone its full-length cDNA and the method applied to create
the viral 50 and 30 ends: (i) The low-copy plasmid pACYC177 (~15 copies/cell) has been utilized to
house a complete cDNA flanked by a 50 bacteriophage T7 promoter and a 30 hepatitis delta virus
ribozyme (HDVr). This T7-HDVr system, analogous to our SP6-PsrI/BarI system, requires an in vitro
transcription and transfection of transcribed RNAs into cells for virus recovery. This “RNA-initiated”
approach has been implemented to clone the viral genomic RNA of the 2010 Cambodian FSS13025
strain [71]. To circumvent the need for a single plasmid containing a full-length cDNA, in vitro
ligation of two or four cDNA fragments pre-cloned individually into the low-copy pACYC177 or
high-copy pUC57 (500–700 copies/cell) plasmid, although relatively inefficient, has been done to
generate a full-length cDNA template prior to in vitro transcription using the T7-HDVr system for
the Ugandan MR-766 (1947), French Polynesian H/PF/2013 (2013), Puerto Rican PRVABC-59 (2015),
and Brazilian SPH2015 (2015) and BeH819015 (2015) strains [49,72]. (ii) The low-copy pACNR1811
(10–20 copies/cell) or high-copy pcDNA6.2 (500–700 copies/cell) plasmid is used to house a full-length
cDNA containing one or two artificial introns to restrict its instability during propagation in E. coli. In
this case, a eukaryotic RNA polymerase (RNAP) II-dependent cytomegalovirus (CMV) promoter is
positioned before the viral 50 end, and a pair of HDVr and an SV40 poly(A) signal/RNAP II terminator
are placed after the viral 30 end. Unlike our SP6-PsrI/BarI system, the CMV-HDVr system requires
transfection of cells with a plasmid carrying the intron-bearing full-length cDNA. This “DNA-initiated”
approach has been applied to clone the viral genomic RNA of the Ugandan MR-766 (1947) and Brazilian
Paraiba (2015) strains [73,74]. Alternatively, a circular form of the intronless full-length cDNA for
the 2015 Brazilian Natal strain has been generated by PCR-mediated joining of eight overlapping
cDNA fragments that are pre-cloned individually into the high-copy pUC plasmid [75]. Although far
less efficient, a similar PCR-based method has also been reported that uses three overlapping cDNA
fragments covering the viral genomic RNA with no joining of these fragments into a circular cDNA [76].
In the present study, we developed a single plasmid-based RNA-initiated reverse genetics system for
ZIKV that not only maximizes the genetic stability of its cloned cDNA using a single-copy BAC as a
vector, but also optimizes the synthesis of infectious RNAs in vitro using the SP6-PsrI/BarI system.
ZIKV circulates in a sylvatic cycle between nonhuman primates (NHPs) and forest-dwelling
mosquitoes, as well as in an urban cycle between humans and town-dwelling mosquitoes [12]. Apart
from NHPs, however, information is scarce on any potential animal hosts or reservoirs for ZIKV
transmission. Using our three cDNA-derived genetically distinct ZIKVs, we evaluated their ability to
infect and replicate in 17 animal cell lines from 12 different species (monkeys, humans, mosquitoes,
mice, cows, pigs, sheep, goats, horses, dogs, cats, and chickens). Our data showed that ZIKV has a
broad cell tropism in vitro, being capable of establishing productive infection in 16 of the 17 cell lines
we tested, although its growth rate and ability to induce CPE varied widely depending on both the
specific virus strain and host cell line. Of particular note, all three ZIKVs grew readily in both porcine
ST and equine NBL-6 cells, with their growth kinetics similar to those observed in simian Vero cells;
generally, they also replicated and spread equally well in ovine SFF-6 cells and in aedine C6/36 cells.
These results raise a question as to whether several agriculturally important domestic animals (e.g.,
pigs, sheep, and horses) are susceptible to ZIKV infection, particularly when young. With respect
to this question, two recent studies have reported that fetal and neonatal piglets are susceptible to
experimental infection with ZIKV [77,78]. Another pilot study has suggested that a range of adult
animals, including rabbits, goats, pigs, cattle, chickens, and ducks, are less likely to act as animal
hosts for ZIKV, based on the levels of viremia and neutralizing antibody titer induced following ZIKV
infection; of these animals, however, rabbits and pigs are proposed to be able to serve as sentinels
for ZIKV surveillance [79]. Clearly, further investigation is needed to elucidate the susceptibility of
these animals to ZIKV infection, preferentially in the presence or absence of type I IFN signaling,
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and might provide new opportunities to increase our understanding of ZIKV biology and to develop
a non-murine model for ZIKV research. Moreover, we discovered a nonsusceptible bovine MDBK
cell line that has a block in ZIKV entry but fully supports the subsequent post-entry steps; however,
this cell line remained highly susceptible to infection by two other enveloped RNA viruses, BVDV [80]
and VSV [81], which like ZIKV [63], enter the cells through clathrin-dependent endocytic pathway.
This ZIKV-nonsusceptible bovine cell line thus offers a unique opportunity to identify the host factors
involved in ZIKV entry.
To our knowledge, this work is the first to generate such a large panel of 13 ZIKV region-specific
antibodies that can identify experimentally nearly all the viral gene products and their related species
in ZIKV-infected Vero cells and define all three structural proteins associated with extracellular
virions. Our data are in overall good agreement with the current model for flavivirus polyprotein
processing [21], but they have also revealed a considerable number of previously undescribed,
presumed cleavage intermediates or further cleavage/degradation products. The main findings from
our study are as follows: (1) While the full-length 13 kDa C and its one or two processed 10 to 11 kDa
proteins were accumulated intracellularly, the extracellular virion-associated C’ protein appeared as
a tightly spaced 12 kDa doublet. (2) For each of the two viral surface glycoproteins (24 kDa prM
and 54/56 kDa E), two or three smaller products were also cell-associated but not virion-associated.
(3) Only the 45 kDa NS1, and not its theoretically frameshift-derived product NS1’, was expressed. (4) In
addition to the intact 14 kDa NS2B, its processed 11 kDa product was also stained, although weakly.
(5) The full-length 69 kDa NS3 was processed to yield multiple truncated species of 33–60 kDa, of which
the C-terminal 34 kDa fragment was the most prominent species. (6) The predicted 16 kDa NS4A was
completely undetectable, but three unpredicted NS4A-related proteins were readily identified, i.e.,
a major doublet at 14 kDa (NS4A’) and two minor protein clusters at 29 kDa (NS4Ap29 ) and 35 kDa
(NS4ABp35 ). (7) Not only the predicted 27 kDa NS4B but also two unpredicted NS4B-related proteins
were observed, one at 11 kDa (NS4Bp11 ) and the other at 35 kDa (NS4ABp35 ). However, the functional
importance of the previously undescribed cleavage intermediates or further cleavage/degradation
products in ZIKV biology remains to be determined.
Much progress has been made over the past year in developing animal models (i.e., mice and
NHPs) for ZIKV [43]. To date, the mouse is the most feasible small animal that mimics aspects of
ZIKV infection in humans, albeit with some limitations resulting from species differences in innate
immunity, reproductive system, and fetal development. Previously, no productive infection was
detected when several strains of immunocompetent adult mice were inoculated peripherally with
diverse ZIKVs, but robust peripheral ZIKV infection causing substantial morbidity and mortality was
observed in both immunocompromised adult and immunocompetent neonatal mice [44,46,82–89].
We call attention, however, to the large variation in ZIKV pathogenicity among the previous studies,
which were conducted by inoculating a variety of ZIKVs into different strains of mice via various
routes. In the current report, we have shown in immunocompetent CD-1 mice at 1, 2, and 4 weeks
of age that ZIKV neuropathogenicity can only be defined in the context of a virus-host combination,
particularly depending on both viral strain and mouse age, as evidenced by comparison of the
neuroinvasiveness and neurovirulence of our three molecularly cloned, genetically distinct ZIKVs: (i)
rMR-766 exhibited neonate-specific age-dependent neuroinvasiveness but displayed a high level of
neurovirulence at all three ages. (ii) rP6-740 had little-to-no neuroinvasiveness at all three ages but
possessed neonate-specific age-dependent neurovirulence. (iii) rPRVABC-59 was non-neuroinvasive
and non-neurovirulent at all three ages. Also, we showed marked differences in IFN sensitivity among
the three ZIKVs: In 4-week-old A129 (IFNAR−/− ) mice, the three ZIKVs were uniformly neurovirulent
but varied in neuroinvasiveness (rMR-766, neuroinvasive; rP6-740, intermediate; and rPRVABC-59,
almost non-neuroinvasive); however, all three ZIKVs, including rPRVABC-59, were neuroinvasive
in age-matched AG129 (IFNAR−/− /IFNGR−/− ) mice. Consistent with previous work, we noted a
greater susceptibility and more severe disease in AG129 mice than in A129 mice [44–49]. In all fatal
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cases, the mortality was related to the productive infection in the brain, coupled with tremors, ataxia,
and hind limb paralysis.
In conclusion, use of our newly developed comparative functional genomics and immunologic
tools, combined with various cell culture and mouse infection model systems, will facilitate further
research leading to ZIKV disease prevention and therapy, as well as an in-depth understanding of
ZIKV biology.
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eliminating the N-glycosylation site at Asn-154 in the viral protein E of rP6-740 is responsible for the observed
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